Evidence map›Paper›PMID 42070269›Full record

ArticleThe Prostate2026

Impact of Genomic Mutations on the Transcriptional Pathways and Tumor Microenvironment Landscape of Localized Early Prostate Cancer.

William Lautert-Dutra, Camila M Melo, Luiz P Chaves, Francisco C Souza, Vida Talebian, Cheryl Crozier, Mary Anne Quintayo, Linda Liao, Dan Dion, Fabiano P Saggioro and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

William Lautert-DutraDepartment of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.ORCID 0000-0002-2372-2431
Camila M MeloDepartment of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Luiz P ChavesDepartment of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Francisco C SouzaDivision of Urology, Department of Surgery and Anatomy, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Vida TalebianDiagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Cheryl CrozierDiagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Mary Anne QuintayoDiagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Linda LiaoDiagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Dan DionDiagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Fabiano P SaggioroDepartment of Pathology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Felipe S AvanteDivision of Urology, Department of Surgery and Anatomy, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Rodolfo B Dos ReisDivision of Urology, Department of Surgery and Anatomy, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Jeremy A SquireDepartment of Genetics, Medical School of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
Jane BayaniDiagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/15011-4Government of Ontario
6 · The paper itself

Abstract

backgroundThe management of intermediate-risk early prostate cancer (PCa) is challenging due to the difficulty in distinguishing indolent from aggressive tumors. This study explores the association between genomic alterations and the tumor and its microenvironment (TME) and implications for disease progression.

methodsWe performed multi-omic profiling in a cohort of 53 localized PCa using targeted sequencing, transcriptional, and proteomic spatial profiling.

resultsSomatic mutations and copy number alterations in RB1 (21%), PTEN (18%), and TP53 (9%) were identified. Kaplan-Meier analysis revealed that alterations in the RB and Cell Cycle pathways, particularly aberrations in PTEN, TP53, or RB1, were associated with shorter biochemical recurrence-free survival (p < 0.001). Spatial proteomic analysis demonstrated a complex immune landscape in patients with mutations. The tumor compartment demonstrated higher expression of immune checkpoint markers, T-cell activation proteins, and proliferation markers; and a TME that is enriched with CD8 + T cells and antigen-presenting cells, but also with immunosuppressive M2 macrophages, suggesting adaptive immune resistance.

conclusionsOur analysis demonstrates that genomic alterations in PTEN, TP53, or RB1 are not only prognostic for poor outcomes but are also associated with a unique, immunologically complex TME in this Brazilian cohort.

Indexed as

MutationProstatic NeoplasmsTumor MicroenvironmentGenomicsHumansMaleProteomicsPTEN PhosphohydrolaseRetinoblastoma Binding ProteinsTumor Suppressor Protein p53Ubiquitin-Protein LigasesPTEN PhosphohydrolasePTEN protein, humanRB1 protein, humanRetinoblastoma Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein Ligasesbiomarkersdigital spatial biologyimmuneprogressionproteomics

Identifiers

PMID42070269
PMCPMC13270082

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.